Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkersWVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and l…